NxThera, also backed by Mitsui and American Medical Systems, aims to use water vapour-based treatments to fight prostate and kidney cancer.
US-based medical device manufacturer NxThera closed a $40m series D round led by medical device maker Boston Scientific yesterday.
The round also featured NxThera’s existing investors, including healthcare advisory company GDN Holdings, investment firm Ally Bridge Group, and venture capital firms Aberdare Ventures and Arboretum Ventures.
Financial services provider East West Bank supplied an undisclosed amount of debt financing as part of the series D.
Founded in 2008, NxThera has developed technology that creates sterile water vapour to treat endourological…
